DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, S. E.
Right arrow Articles by McIntee, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, S. E.
Right arrow Articles by McIntee, E. J.

Vol. 28, Issue 11, 1263-1266, November 2000

SHORT COMMUNICATION
Specificity of Cytochrome P450 2A3-Catalyzed alpha -Hydroxylation of N'-Nitrosonornicotine Enantiomers

Sharon E. Murphy, Issa S. Isaac, Xinxin Ding, and Edward J. McIntee

Department of Biochemistry
Molecular Biology & Biophysics
University of Minnesota Cancer Center
Minneapolis, Minnesota
(S.E.M., I.S.I., E.J.M.); and
The Laboratory of Human Toxicology
and Molecular Epidemiology
Wadsworth Center
New York State Department of Health
Albany, New York (X.D.)

N'-nitrosonornicotine (NNN) induces tumors in the rat nasal cavity and esophagus and is believed to be a causative agent for esophageal cancer in tobacco users. To exert its carcinogenic potential, NNN must be metabolically activated by alpha -hydroxylation at either the 2'- or 5'-carbon. We previously reported that the human cytochrome P450 (P450), 2A6, efficiently and specifically catalyzed NNN 5'-hydroxylation. P450 2A3, which is expressed in the rat nasal cavity and to a small extent in the esophagus, is closely related to P450 2A6. P450 2A3, like 2A6, is a good catalyst of NNN alpha -hydroxylation (Km 7 µM; Vmax 17 nmol/min/nmol). However, in contrast to P450 2A6, 2A3 catalyzed both 5'- and 2'-hydroxylation of NNN. The ratio of 2'- to 5'-hydroxylation was 1:3. These data, both with P450 2A6 and 2A3, were obtained using racemic NNN. P450 2A3 catalyzed metabolism of (S)-NNN occurred exclusively at the 5'-position. The predominant pathway of (R)-NNN metabolism was 2'-hydroxylation, and occurred to a 3-fold greater extent than did 5'-hydroxylation. These data are in contrast to those obtained from a recent study of (R)- and (S)-NNN metabolism by cultured rat esophagus. In that study, (S)-NNN was metabolized predominantly by 2'-hydroxylation and (R)-NNN equally by 2'- and 5'-hydroxylation. Taken together, these data provide strong evidence that P450 2A3 is not the rat esophageal P450 that catalyzes the metabolic activation of NNN. P450 2A3 may be an important catalyst of NNN activation in rat nasal mucosa.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
CarcinogenesisHome page
L. B. von Weymarn, J. A. Chun, and P. F. Hollenberg
Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers
Carcinogenesis, April 1, 2006; 27(4): 782 - 790.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. B. von Weymarn, Q.-Y. Zhang, X. Ding, and P. F. Hollenberg
Effects of 8-methoxypsoralen on cytochrome P450 2A13
Carcinogenesis, March 1, 2005; 26(3): 621 - 629.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. L. Wong, S. E. Murphy, M. Wang, and S. S. Hecht
Comparative metabolism of N-nitrosopiperidine and N-nitrosopyrrolidine by rat liver and esophageal microsomes and cytochrome P450 2A3
Carcinogenesis, February 1, 2003; 24(2): 291 - 300.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.